April 2013 On December 11–12, 2012, in Washington, D.C., Treatment Action Group (TAG) hosted a meeting of HIV advocates, service providers, and researchers from across the United States (U.S.) to review the current state of the national HIV response and…
March 6, 2013 Advances in HIV treatment research in 2010 and 2011 saw improvement in treatment regimens and strategies, and reinvigorated optimism for finding a cure. In 2012, TAG and AVAC, with financial support from UNAIDS, put forth a collaborative…
by Tim Horn Fact: If we’re going to make headway in preventing and treating non-AIDS-related health complications among people with HIV, which are very much on the rise and a serious risk to disease-free survival, we’re going to need the…
The HIV community is bracing for impact as acrimonious federal budgetary battles rage on. by Coco Jervis The eleventh hour “fiscal cliff” deal reached by Congress and the Obama administration on New Year’s Eve leaves much to be desired. By…
The bold, aggressive new plan released by Hillary Clinton once again wildly surpasses in ambition what U.S. officials dare attempt in this country. This article was first published on December 1, 2012, in theAtlantic.com. by Mark Harrington On Thursday, outgoing…
A brilliant HIV treatment activist, Spencer Cox directed TAG’s Antiviral Project from 1994–1999. He died of AIDS on December 18, 2012. Peter Staley delivered this eulogy at his memorial gathering in New York City on January 20, 2013.
Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.
Today in New York, Spencer Cox died. He was one of the most brilliant of the first generation of AIDS treatment activists.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.